CR20120024A - Diferenciación de células madre mesenquimales - Google Patents

Diferenciación de células madre mesenquimales

Info

Publication number
CR20120024A
CR20120024A CR20120024A CR20120024A CR20120024A CR 20120024 A CR20120024 A CR 20120024A CR 20120024 A CR20120024 A CR 20120024A CR 20120024 A CR20120024 A CR 20120024A CR 20120024 A CR20120024 A CR 20120024A
Authority
CR
Costa Rica
Prior art keywords
mesenquimal
differentiation
mother cells
mother
cells
Prior art date
Application number
CR20120024A
Other languages
English (en)
Spanish (es)
Inventor
Kristen Johnson
Lori Jennings
Peter Schultz
Original Assignee
Irm Llc
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43450138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120024(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc, Scripps Research Inst filed Critical Irm Llc
Publication of CR20120024A publication Critical patent/CR20120024A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CR20120024A 2009-07-14 2012-01-16 Diferenciación de células madre mesenquimales CR20120024A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22529309P 2009-07-14 2009-07-14

Publications (1)

Publication Number Publication Date
CR20120024A true CR20120024A (es) 2012-06-11

Family

ID=43450138

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120024A CR20120024A (es) 2009-07-14 2012-01-16 Diferenciación de células madre mesenquimales

Country Status (30)

Country Link
US (4) US9139633B2 (instruction)
EP (1) EP2453921B1 (instruction)
JP (1) JP5602850B2 (instruction)
KR (3) KR20180000337A (instruction)
CN (2) CN105601728B (instruction)
AU (1) AU2010273570B2 (instruction)
BR (1) BR112012000914B8 (instruction)
CA (1) CA2767826C (instruction)
CL (1) CL2012000091A1 (instruction)
CO (1) CO6491059A2 (instruction)
CR (1) CR20120024A (instruction)
CU (1) CU24042B1 (instruction)
EA (1) EA023073B1 (instruction)
EC (1) ECSP12011604A (instruction)
ES (1) ES2541217T3 (instruction)
GT (1) GT201200011A (instruction)
IL (2) IL217383A (instruction)
IN (1) IN2012DN00572A (instruction)
MA (1) MA33423B1 (instruction)
MX (1) MX2012000707A (instruction)
MY (1) MY160951A (instruction)
NZ (1) NZ597306A (instruction)
PE (2) PE20120570A1 (instruction)
PL (1) PL2453921T3 (instruction)
PT (1) PT2453921E (instruction)
SG (1) SG177318A1 (instruction)
TN (1) TN2011000655A1 (instruction)
UA (1) UA104031C2 (instruction)
WO (1) WO2011008773A2 (instruction)
ZA (1) ZA201200078B (instruction)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA023073B1 (ru) * 2009-07-14 2016-04-29 Дзе Скриппс Рисёч Инститьют Способы и композиции для лечения или предупреждения артрита или повреждения сустава
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
CN104185988B (zh) 2011-11-08 2019-05-10 韩国电子通信研究院 用于共享候选者列表的方法和装置
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
WO2014004465A1 (en) * 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Targeted therapeutics
JO3564B1 (ar) * 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
JP6579623B2 (ja) 2013-03-15 2019-09-25 ザ・スクリップス・リサーチ・インスティテュート 軟骨形成を誘導するための化合物及び方法
JO3563B1 (ar) 2014-05-13 2020-07-05 Novartis Ag مركبات وتركيبات لتحفيز تكوين الغضاريف
CN104840486A (zh) * 2015-04-30 2015-08-19 北京益诺勤生物技术有限公司 一种组合物及其应用、制剂
CN109069868B (zh) 2016-03-03 2023-06-06 瑞泽恩制药公司 通过施用与angptl3抑制剂组合的pcsk9抑制剂治疗高脂血症患者的方法
EP3538127A1 (en) * 2016-11-14 2019-09-18 Novartis AG Methods and compositions for treatment of cartilage damage and arthritis
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
WO2020115683A1 (en) 2018-12-06 2020-06-11 Novartis Ag 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
US12365692B2 (en) 2018-12-06 2025-07-22 Novartis Ag 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
CN109432128A (zh) * 2018-12-07 2019-03-08 卡替（上海）生物技术股份有限公司 牙髓间充质干细胞在银屑病治疗中的应用
KR102246582B1 (ko) * 2019-04-03 2021-04-30 이화여자대학교 산학협력단 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
WO1999058660A1 (en) * 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
WO1999055869A1 (en) 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
AU4643699A (en) 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
KR20010104373A (ko) 1999-03-08 2001-11-24 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
ES2291198T3 (es) * 1999-07-20 2008-03-01 Genentech, Inc. Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico.
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20030120056A1 (en) * 2000-10-16 2003-06-26 Audrey Goddard TIE ligand homologues
ATE544855T1 (de) 2000-10-16 2012-02-15 Genentech Inc Wisp polypeptide, und deren therapeutische anwendungen
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
ES2429034T3 (es) * 2001-11-16 2013-11-12 Genentech, Inc. Uso de antagonistas de ANGPTL3 para el tratamiento de enfermedades hepáticas
EP1546235B1 (en) * 2002-09-09 2021-10-20 Nektar Therapeutics Water-soluble polymer alkanals
CN1761749A (zh) * 2003-03-10 2006-04-19 独立行政法人科学技术振兴机构 检测间充质干细胞的标记和采用该标记识别间充质干细胞的方法
JP3979372B2 (ja) 2003-09-26 2007-09-19 ブラザー工業株式会社 画像処理装置、画像処理方法及び画像処理プログラム
JP5269411B2 (ja) * 2004-06-21 2013-08-21 ザ クリーブランド クリニック ファウンデーション 幹細胞をホーミングさせるためのｃｃｒリガンド
EP1863340A2 (en) 2005-03-11 2007-12-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP5139271B2 (ja) 2005-05-24 2013-02-06 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 培養した造血幹細胞を拡大しかつ分析する方法
US7601501B2 (en) * 2006-08-11 2009-10-13 The Scripps Research Institute Controlling osteogenesis by inhibition of osteogenic suppressors
WO2008137641A2 (en) 2007-05-04 2008-11-13 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
EA023073B1 (ru) * 2009-07-14 2016-04-29 Дзе Скриппс Рисёч Инститьют Способы и композиции для лечения или предупреждения артрита или повреждения сустава
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل

Also Published As

Publication number Publication date
ZA201200078B (en) 2013-01-30
CL2012000091A1 (es) 2012-10-26
SG177318A1 (en) 2012-03-29
US9139633B2 (en) 2015-09-22
US20120177644A1 (en) 2012-07-12
EP2453921A2 (en) 2012-05-23
EA023073B1 (ru) 2016-04-29
CU24042B1 (es) 2014-11-27
EA201200118A1 (ru) 2012-09-28
WO2011008773A3 (en) 2011-08-25
PE20160507A1 (es) 2016-05-20
NZ597306A (en) 2014-03-28
EP2453921A4 (en) 2012-12-19
ECSP12011604A (es) 2012-06-29
KR20160015403A (ko) 2016-02-12
UA104031C2 (uk) 2013-12-25
MY160951A (en) 2017-03-31
BR112012000914A8 (pt) 2017-12-19
PL2453921T3 (pl) 2015-11-30
US11241482B2 (en) 2022-02-08
IL217383A0 (en) 2012-02-29
BR112012000914A2 (pt) 2017-08-08
CN102625830A (zh) 2012-08-01
IL247310B (en) 2018-04-30
MA33423B1 (fr) 2012-07-03
CN105601728B (zh) 2020-01-10
CN105601728A (zh) 2016-05-25
CO6491059A2 (es) 2012-07-31
AU2010273570A1 (en) 2012-02-02
JP5602850B2 (ja) 2014-10-08
US10064918B2 (en) 2018-09-04
PT2453921E (pt) 2015-09-25
CU20120007A7 (es) 2013-02-26
US20190000922A1 (en) 2019-01-03
CA2767826A1 (en) 2011-01-20
KR20120029472A (ko) 2012-03-26
IN2012DN00572A (instruction) 2015-06-12
KR20180000337A (ko) 2018-01-02
AU2010273570B2 (en) 2014-07-03
JP2012533549A (ja) 2012-12-27
MX2012000707A (es) 2012-03-21
KR101590834B1 (ko) 2016-02-12
CA2767826C (en) 2015-11-24
EP2453921B1 (en) 2015-05-27
ES2541217T3 (es) 2015-07-16
PE20120570A1 (es) 2012-05-19
WO2011008773A2 (en) 2011-01-20
CN102625830B (zh) 2016-03-02
US20160213748A1 (en) 2016-07-28
HK1164169A1 (en) 2012-09-21
BR112012000914B8 (pt) 2021-05-25
TN2011000655A1 (en) 2013-05-24
IL217383A (en) 2016-08-31
US20200108122A1 (en) 2020-04-09
BR112012000914B1 (pt) 2021-04-06
GT201200011A (es) 2013-12-10
US10555990B2 (en) 2020-02-11

Similar Documents

Publication Publication Date Title
CR20120024A (es) Diferenciación de células madre mesenquimales
UY34387A (es) Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización.
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
CL2015002301A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxílico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c.
BR112013016535A2 (pt) extratos vegetais para o tratamento e prevenção de infecções
CR20140576A (es) Sintesis de compuestos heterociclicos
BR112013024401A2 (pt) métodos e composições para o tratamento do transtorno do déficit de atenção
BRPI1014759A2 (pt) composto útil para o tratamento de doenças degenerativas e inflamatórias
UY34037A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
CU20140025A7 (es) Pirimidinas anilladas sustituidas
CO6930356A2 (es) Compuestos inhibidores de metaloenzimas
CO7020867A2 (es) Formulaciones de anticuerpo y metodos
DK2588154T3 (da) Sammensætning omfattende calciumphosphat, sulfatpulvere eller dmb anvendt i behandlingen af degenerative knogletilstande
BRPI0916862A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
BR112012018986A2 (pt) sistemas e métodos para redução de lodos produzidos por estações de tratamento de águas residuais
CL2010001641A1 (es) Compuestos derivados de heterociclos biciclicos sustituidos; composicion farmaceutica; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas e inflamatorias tales como cancer y artritis reumatoide entre otras.
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
BR112013004165A2 (pt) métodos para o tratamento ou profilaxia da trombose ou embolia
UY34616A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
BR112014004416A2 (pt) composições e métodos para o tratamento de doenças neurodegenerativas
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
IL223290A (en) Anti-1α-il antibodies for the treatment of arthritis